Cargando…

Comparative analysis on the anti-inflammatory/immune effect of mesenchymal stem cell therapy for the treatment of pulmonary arterial hypertension

Despite the advancement of targeted therapy for pulmonary arterial hypertension (PAH), poor prognosis remains a reality. Mesenchymal stem cells (MSCs) are one of the most clinically feasible alternative treatment options. We compared the treatment effects of adipose tissue (AD)-, bone marrow (BD)-,...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Seyeon, Jang, Albert Y., Chae, Sehyun, Choi, Seungbum, Moon, Jeongsik, Kim, Minsu, Spiekerkoetter, Edda, Zamanian, Roham T., Yang, Phillip C., Hwang, Daehee, Byun, Kyunghee, Chung, Wook-Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7820276/
https://www.ncbi.nlm.nih.gov/pubmed/33479312
http://dx.doi.org/10.1038/s41598-021-81244-1
_version_ 1783639175662141440
author Oh, Seyeon
Jang, Albert Y.
Chae, Sehyun
Choi, Seungbum
Moon, Jeongsik
Kim, Minsu
Spiekerkoetter, Edda
Zamanian, Roham T.
Yang, Phillip C.
Hwang, Daehee
Byun, Kyunghee
Chung, Wook-Jin
author_facet Oh, Seyeon
Jang, Albert Y.
Chae, Sehyun
Choi, Seungbum
Moon, Jeongsik
Kim, Minsu
Spiekerkoetter, Edda
Zamanian, Roham T.
Yang, Phillip C.
Hwang, Daehee
Byun, Kyunghee
Chung, Wook-Jin
author_sort Oh, Seyeon
collection PubMed
description Despite the advancement of targeted therapy for pulmonary arterial hypertension (PAH), poor prognosis remains a reality. Mesenchymal stem cells (MSCs) are one of the most clinically feasible alternative treatment options. We compared the treatment effects of adipose tissue (AD)-, bone marrow (BD)-, and umbilical cord blood (UCB)-derived MSCs in the rat monocrotaline-induced pulmonary hypertension (PH) model. The greatest improvement in the right ventricular function was observed in the UCB-MSCs treated group. The UCB-MSCs treated group also exhibited the greatest improvement in terms of the largest decrease in the medial wall thickness, perivascular fibrosis, and vascular cell proliferation, as well as the lowest levels of recruitment of innate and adaptive immune cells and associated inflammatory cytokines. Gene expression profiling of lung tissue confirmed that the UCB-MSCs treated group had the most notably attenuated immune and inflammatory profiles. Network analysis further revealed that the UCB-MSCs group had the greatest therapeutic effect in terms of the normalization of all three classical PAH pathways. The intravenous injection of the UCB-MSCs, compared with those of other MSCs, showed superior therapeutic effects in the PH model for the (1) right ventricular function, (2) vascular remodeling, (3) immune/inflammatory profiles, and (4) classical PAH pathways.
format Online
Article
Text
id pubmed-7820276
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-78202762021-01-22 Comparative analysis on the anti-inflammatory/immune effect of mesenchymal stem cell therapy for the treatment of pulmonary arterial hypertension Oh, Seyeon Jang, Albert Y. Chae, Sehyun Choi, Seungbum Moon, Jeongsik Kim, Minsu Spiekerkoetter, Edda Zamanian, Roham T. Yang, Phillip C. Hwang, Daehee Byun, Kyunghee Chung, Wook-Jin Sci Rep Article Despite the advancement of targeted therapy for pulmonary arterial hypertension (PAH), poor prognosis remains a reality. Mesenchymal stem cells (MSCs) are one of the most clinically feasible alternative treatment options. We compared the treatment effects of adipose tissue (AD)-, bone marrow (BD)-, and umbilical cord blood (UCB)-derived MSCs in the rat monocrotaline-induced pulmonary hypertension (PH) model. The greatest improvement in the right ventricular function was observed in the UCB-MSCs treated group. The UCB-MSCs treated group also exhibited the greatest improvement in terms of the largest decrease in the medial wall thickness, perivascular fibrosis, and vascular cell proliferation, as well as the lowest levels of recruitment of innate and adaptive immune cells and associated inflammatory cytokines. Gene expression profiling of lung tissue confirmed that the UCB-MSCs treated group had the most notably attenuated immune and inflammatory profiles. Network analysis further revealed that the UCB-MSCs group had the greatest therapeutic effect in terms of the normalization of all three classical PAH pathways. The intravenous injection of the UCB-MSCs, compared with those of other MSCs, showed superior therapeutic effects in the PH model for the (1) right ventricular function, (2) vascular remodeling, (3) immune/inflammatory profiles, and (4) classical PAH pathways. Nature Publishing Group UK 2021-01-21 /pmc/articles/PMC7820276/ /pubmed/33479312 http://dx.doi.org/10.1038/s41598-021-81244-1 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Oh, Seyeon
Jang, Albert Y.
Chae, Sehyun
Choi, Seungbum
Moon, Jeongsik
Kim, Minsu
Spiekerkoetter, Edda
Zamanian, Roham T.
Yang, Phillip C.
Hwang, Daehee
Byun, Kyunghee
Chung, Wook-Jin
Comparative analysis on the anti-inflammatory/immune effect of mesenchymal stem cell therapy for the treatment of pulmonary arterial hypertension
title Comparative analysis on the anti-inflammatory/immune effect of mesenchymal stem cell therapy for the treatment of pulmonary arterial hypertension
title_full Comparative analysis on the anti-inflammatory/immune effect of mesenchymal stem cell therapy for the treatment of pulmonary arterial hypertension
title_fullStr Comparative analysis on the anti-inflammatory/immune effect of mesenchymal stem cell therapy for the treatment of pulmonary arterial hypertension
title_full_unstemmed Comparative analysis on the anti-inflammatory/immune effect of mesenchymal stem cell therapy for the treatment of pulmonary arterial hypertension
title_short Comparative analysis on the anti-inflammatory/immune effect of mesenchymal stem cell therapy for the treatment of pulmonary arterial hypertension
title_sort comparative analysis on the anti-inflammatory/immune effect of mesenchymal stem cell therapy for the treatment of pulmonary arterial hypertension
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7820276/
https://www.ncbi.nlm.nih.gov/pubmed/33479312
http://dx.doi.org/10.1038/s41598-021-81244-1
work_keys_str_mv AT ohseyeon comparativeanalysisontheantiinflammatoryimmuneeffectofmesenchymalstemcelltherapyforthetreatmentofpulmonaryarterialhypertension
AT jangalberty comparativeanalysisontheantiinflammatoryimmuneeffectofmesenchymalstemcelltherapyforthetreatmentofpulmonaryarterialhypertension
AT chaesehyun comparativeanalysisontheantiinflammatoryimmuneeffectofmesenchymalstemcelltherapyforthetreatmentofpulmonaryarterialhypertension
AT choiseungbum comparativeanalysisontheantiinflammatoryimmuneeffectofmesenchymalstemcelltherapyforthetreatmentofpulmonaryarterialhypertension
AT moonjeongsik comparativeanalysisontheantiinflammatoryimmuneeffectofmesenchymalstemcelltherapyforthetreatmentofpulmonaryarterialhypertension
AT kimminsu comparativeanalysisontheantiinflammatoryimmuneeffectofmesenchymalstemcelltherapyforthetreatmentofpulmonaryarterialhypertension
AT spiekerkoetteredda comparativeanalysisontheantiinflammatoryimmuneeffectofmesenchymalstemcelltherapyforthetreatmentofpulmonaryarterialhypertension
AT zamanianrohamt comparativeanalysisontheantiinflammatoryimmuneeffectofmesenchymalstemcelltherapyforthetreatmentofpulmonaryarterialhypertension
AT yangphillipc comparativeanalysisontheantiinflammatoryimmuneeffectofmesenchymalstemcelltherapyforthetreatmentofpulmonaryarterialhypertension
AT hwangdaehee comparativeanalysisontheantiinflammatoryimmuneeffectofmesenchymalstemcelltherapyforthetreatmentofpulmonaryarterialhypertension
AT byunkyunghee comparativeanalysisontheantiinflammatoryimmuneeffectofmesenchymalstemcelltherapyforthetreatmentofpulmonaryarterialhypertension
AT chungwookjin comparativeanalysisontheantiinflammatoryimmuneeffectofmesenchymalstemcelltherapyforthetreatmentofpulmonaryarterialhypertension